Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2023 · 10-Q
Revenue$19.98M$19.98M−38.8% vs Q2 2022 Net Income-$72.06M-$72.06MN/M vs Q2 2022 EPS Diluted-$1.66-$1.66N/M vs Q2 2022 Operating Income-$73,108,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$49,899,000N/M Margins · derivedOperating margin-366.0%−174.4 pt vs Q2 2022
Net margin-360.7%−151.9 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 2, 2023 · 33 d after period end